PARP Inhibitors

Cat.No.	Product Name	Information	Product Use Citations
S1060	AZD2281 (Olaparib)	Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Olaparib induces significant autophagy that is associated with mitophagy in cells with BRCA mutations.	Cell, 2025, 188(18):5081-5099.e27 Cancer Cell, 2025, 43(8):1530-1548.e9 Cancer Cell, 2025, 43(4):776-796.e14
S1180	XAV-939	XAV-939 (NVP-XAV939) selectively inhibits Wnt/β-catenin-mediated transcription through tankyrase1/2 inhibition with IC50 of 11 nM/4 nM in cell-free assays, regulates axin levels and does not affect CRE, NF-κB or TGF-β.	Nat Biotechnol, 2025, 10.1038/s41587-025-02649-1 Nat Cell Biol, 2025, 27(8):1240-1255 Nat Cell Biol, 2025, NONE
S7048	BMN-673 (Talazoparib)	Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.	Mol Cancer, 2025, 24(1):217 Nat Commun, 2025, 16(1):8476 Nat Commun, 2025, 16(1):6972
S1004	Veliparib (ABT-888)	Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with K_i of 5.2 nM and 2.9 nM in cell-free assays, respectively. This compound is inactive to SIRT2 and increases autophagy and apoptosis. Phase 3.	Nat Commun, 2025, 16(1):8476 Nat Commun, 2025, 16(1):1026 J Exp Med, 2025, 222(5)e20241184
S1098	Rucaparib phosphate	Rucaparib phosphate is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.	Mol Cell, 2025, S1097-2765(25)00098-X Cells, 2025, 14(14)1049 Cancer Res Commun, 2025, 10.1158/2767-9764.CRC-24-0515
S2741	Niraparib (MK-4827)	Niraparib (MK-4827) is a selective inhibitor of PARP1/2 with IC50 of 3.8 nM/2.1 nM, with great activity in cancer cells with mutant BRCA-1 and BRCA-2. It is >330-fold selective against PARP3, V-PARP and Tank1. This compound can form PARP–DNA complexes resulting in DNA damage, apoptosis, and cell death. Phase 3.	Nat Commun, 2025, 16(1):4239 Cancer Commun (Lond), 2025, 45(12):1706-1733. Neuro Oncol, 2025, noaf061
S4948	Rucaparib (AG-014699)	Rucaparib is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains.	Cancer Res, 2025, 10.1158/0008-5472.CAN-24-2938 Cancer Lett, 2025, 613:217505 Stem Cell Res Ther, 2025, 16(1):548
S7300	PJ34 HCl	PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.	Nucleic Acids Res, 2025, 53(20)gkaf1090 Cell Death Differ, 2025, 10.1038/s41418-025-01457-z J Neuroinflammation, 2024, 21(1):235
S7625	Niraparib tosylate	Niraparib tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM. Niraparib increases formation of PARP-DNA complexes resulting in DNA damage, apoptosis, and cell death.	Cancer Res Commun, 2025, 10.1158/2767-9764.CRC-24-0515 Nat Commun, 2024, 15(1):9463 Nat Commun, 2024, 15(1):1041
S2178	AG-14361	AG14361 is a potent inhibitor of PARP1 with K_i of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.	Cell Rep, 2025, 44(4):115457 PLoS One, 2025, 20(3):e0318267 Nat Commun, 2024, 15(1):1041
S1087	Iniparib (BSI-201)	Iniparib (BSI-201, NSC-746045, IND-71677) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.	Cancer Res, 2025, 10.1158/0008-5472.CAN-24-2938 Nat Commun, 2024, 15(1):10347 Nat Commun, 2021, 12(1):736
S5195	Rucaparib Camsylate	Rucaparib (Rubraca, AG014699, PF01367338) Camsylate is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains.	Cells, 2024, 13(16)1348 Adv Sci (Weinh), 2022, 9(30):e2201210 Cell Death Dis, 2022, 13(6):558
S8592	Pamiparib	Pamiparib is a potent and selective inhibitor of PARP1 and PARP2 with IC50 values of 0.83 and 0.11 nM, respectively in biochemical assays. It shows high selectivity over other PARP enzymes.	United Eur Gastroent, 2025, 13(7):1328-1342 Cell Death Discov, 2024, 10(1):74 Cells, 2024, 13(16)1348
S7239	G007-LK	G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.	EBioMedicine, 2024, 103:105129 NPJ Precis Oncol, 2024, 8(1):264 bioRxiv, 2024, 2024.02.02.578667
S2197	A-966492	A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with K_i of 1 nM and 1.5 nM, respectively.	Nat Commun, 2021, 12(1):736 Front Immunol, 2021, 12:712021 bioRxiv, 2021, 10.1101/2020.10.18.333070
S8038	UPF 1069	UPF 1069 is a selective PARP2 inhibitor with IC50 of 0.3 μM. It is ~27-fold selective against PARP1.	Autophagy, 2025, 1-17. Cancer Lett, 2025, 613:217505 Cell Rep, 2023, 42(9):113113
S8419	Stenoparib (E7449)	Stenoparib (E7449, 2X-121, MGI25036) is an orally bioavailable, brain penetrable, small molecule dual inhibitor of PARP1/2 and also inhibits PARP5a/5b, otherwise known as tankyrase1 and 2 (TNKS1/2), important regulators of canonical Wnt/β-catenin signaling. It has IC50 values of 1.0 and 1.2 nM for PARP1 and 2, respectively.	Cancer Lett, 2025, 613:217505 Br J Pharmacol, 2024, 10.1111/bph.17305 Cell Death Discov, 2024, 10(1):74
S7029	AZD2461	AZD2461 is a novel PARP inhibitor with low affinity for Pgp. Phase 1.	Nat Commun, 2021, 12(1):736 Cell Chem Biol, 2021, S2451-9456(21)00058-1 Dev Cell, 2020, 53(2):240-252.e7
S7438	ME0328	ME0328 is a potent and selective PARP inhibitor with IC50 of 0.89 μM for PARP3, about 7-fold selectivity over PARP1.	iScience, 2025, 28(4):112267 Mol Med, 2025, 31(1):216 Biomed Pharmacother, 2018, 97:115-119
S8363	NMS-P118	NMS-P118 is a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles, showing 150-fold selectivity for PARP-1 over PARP-2 (Kd 0.009 μM vs 1.39 μM, respectively).	Cancer Lett, 2025, 613:217505 Res Sq, 2023, rs.3.rs-2688694 Int J Biol Sci, 2022, 18(3):1238-1253
S1132	3-Aminobenzamide	3-Aminobenzamide (3-ABA , 3-Amino Benzamide, 3-AB) is a potent inhibitor of Poly(ADP-ribose)polymerase (PARP) and inhibits cell apoptosis after SCI (Spinal Cord Injury) in caspase-independent way.	J Biol Chem, 2024, S0021-9258(24)02608-5 Int J Mol Sci, 2023, 24(2)1667 Psychopharmacology (Berl), 2022, 10.1007/s00213-022-06188-4
S7238	NVP-TNKS656	NVP-TNKS656 is a highly potent, selective, and orally active tankyrase inhibitor with IC50 of 6 nM for TNKS2, > 300-fold selectivity against PARP1 and PARP2.	Nat Commun, 2025, 16(1):4945 Dev Cell, 2025, S1534-5807(25)00496-4 Cell, 2024, 187(14):3671-3689.e23
S8370	BGP-15 2HCl	BGP-15, is a nicotinic amidoxime derivative with PARP inhibitory activity. It has been demonstrated that BGP-15 protects against ischemia-reperfusion injury.	Part Fibre Toxicol, 2023, 20(1):28 Respir Res, 2023, 24(1):319 UNIVERSITY OF GRAZ, 2021,
S9875	AZD5305 (Saruparib)	Saruparib (AZD5305) is a highly selective and potent inhibitor of PARP1 with an IC50 of 3 nM in wild-type A549 lung cancer cells. AZD5305 shows no or minimal growth inhibitory effects in other cells (IC50s >10μM).	Nature, 2024, 10.1038/s41586-024-07217-2 Nature, 2024, 628(8007):433-441 Nat Commun, 2024, 15(1):5822
S7730	NU1025	NU1025 (NSC 696807) is a potent PARP inhibitor with IC50 of 400 nM.	J Natl Cancer Cent, 2024, 4(3):263-279 J Clin Med, 2020, 30;9(4) Med Sci Monit, 2019, 25:2886-2895
S7490	WIKI4	WIKI4 is a novel Tankyrase inhibitor with IC50 of 15 nM for TNKS2, and leads to inhibition of Wnt/beta-catenin signaling.	Sci Rep, 2022, 12(1):7 Carcinogenesis, 2020, 41(7):993-1004 Nat Commun, 2019, 10(1):4363
S4715	Benzamide	Benzamide, a derivative of benzoic acid, is an inhibitor of poly(ADP-ribose) polymerase with an IC50 of 3.3 μM.	Int J Mol Sci, 2019, 20(21) Mol Pharmacol, 2019, 96(4):419-429 Acta Neuropathol Commun, 2014, 2:57
S9712	Fluzoparib (SHR-3162)	Fluzoparib (SHR3162, HS10160) is a potent Poly (ADP-ribose) polymerase (PARP) inhibitor that shows anti-tumor activity, with an IC50 of 1.46±0.72 nM for PARP1.	iScience, 2024, 27(10):110862 Biochemistry, 2023, 62(16):2382-2390
S4710	Picolinamide	Picolinamide (2-Pyridinecarboxamide, Picolinoylamide, 2-Carbamoylpyridine) is found to be a strong inhibitor of poly (ADP-ribose) synthetase of nuclei from rat pancreatic islet cells.	Neural Regen Res, 2023, 18(10):2252-2259
S0519	BYK204165	BYK204165 is a potent and selective inhibitor of the poly(ADP-ribose) polymerase (PARP). This compound inhibits cell-free recombinant human PARP-1 (hPARP-1) with pIC50 of 7.35 and pKi of 7.05 and murine PARP-2 (mPARP-2) with pIC50 of 5.38, respectively.	Sci Transl Med, 2021, 13(592)eabc7211
S8993	Atamparib (RBN-2397)	RBN-2397 (Atamparib) is a potent, selective and orally active NAD+ competitive inhibitor PARP7 with IC50 of <3 nM and Kd of <0.001 μM. This compound has the potential for the research of tumor treatment.	bioRxiv, 2024, 2024.03.15.584457
S8992	RBN012759	RBN012759 is a potent and selective inhibitor of PARP14 with IC50 of <3 nM and 5 nM for human catalytic domain and mouse catalytic domain, respectively. This compound contributes to anti-tumor immune response.	Cell Mol Gastroenterol Hepatol, 2025, S2352-345X(25)00080-3
E2147	AZD9574 (Palacaparib)	AZD9574 is a novel PARP inhibitor which combines PARP1 selectivity, trapping and high CNS penetration in a single molecule.	Sci Adv, 2024, 10(46):eadp6567
E1425	Nesuparib	Nesuparib (JPI-547, NOV140201) is a potential inhibitor of both PARP and tankyrases, with IC50 of 0.005 μM, 0.001 μM, 0.002 μM, and ND for TNKS1, TNKS2, PARP1, and PARP2, respectively. This compound exhibits anti-tumor activity in BRCA-deficient xenograft models.
S6977	DR2313	DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively.
S6739	MN 64	MN-64 is a potent inhibitor of TNKS1 and TNKS2 with IC50 value of 6 and 72 nM, respectively.
E5842^New	Nudifloramide	Nudifloramide (2PY, N-methyl-2-pyridone-5- carboxamide) is a pyridine derivative of nicotinamide that inhibits PARP-1 (poly (ADP-ribose) polymerase-1) activity in vitro, with an IC50 of 8 µM.
E1069	M2912	M2912 (MSC2504877) is a very potent TNKS1/TNKS2 inhibitor (IC50=0.6 nM for TNKS1) with exquisite selectivity over other PARP family enzymes and favorable compound properties. This inhibitor potently modulates the Wnt/β-catenin pathway by elevating the levels of axin2 (EC50=17 nM) and tankyrase in DLD1 cells in a dose-dependent manner resulting in reduced cellular Wnt reporter activity.
S0732	GeA-69	GeA-69 is a cell-permeable, selective allosteric inhibitor targeting macrodomain 2 (MD2) of poly-adenosine-diphosphate-ribose polymerase 14 (PARP14) with Kd of 860 nM.
E1912	B102(PARP/HDAC-IN-1)	B102(PARP/HDAC-IN-1) is a dual inhibitor of PARP and HDAC, with IC50 of 19.01 nM, 2.13 nM, 1.69 μM, > 10 μM for PARP1, PARP2, HDAC1, HDAC6, respectively, in an enzymatic assay. It exhibits anti-proliferative and anti-tumor effects. It also induces DNA damage and apoptosis in vitro.
E1614	OUL232	OUL232 (Compound 27) is an potent inhibitor of mono-ADP-ribosylation (mono-ARTs) PARP10 with IC50 of 7.8 nM. It also inhibits PARP7, PARP11, PARP12, PARP14, and PARP15 at nM potencies.
S9893	Venadaparib(IDX-1197)	Venadaparib (IDX-1197), a potent PARP1/2 inhibitor with IC50 values of 1.4 nM and 1.0 nM respectively, prevents the repair of DNA single-strand breaks (SSB) and promotes the conversion of SSB to double-stranded breaks (DSB), which ultimately leads to synthetic lethality in cancer cells.
E4942^New	Talazoparib tosylate	Talazoparib tosylate (BMN 673ts) is a potent, orally bioavailable PARP1/2 inhibitor exhibiting an IC50 of 0.57 nM against PARP1.
E4869	Niraparib hydrochloride	Niraparib hydrochloride (MK-4827 hydrochloride) is a potent poly(ADP-ribose)polymerase (PARP) inhibitor with IC50s of 3.8 and 2.1 nM against both the PARP-1 and PARP-2 enzymes, respectively.It inhibits the repair of radiation-induced DNA double-strand breaks, activates apoptosis, and exhibits anti-tumor activity.
S9360	4-Hydroxyquinazoline	4-Hydroxyquinazoline (Quinazolin-4-ol, 4-Quinazolinol) is a PARP inhibitor with a high potency for PARP-1 with IC50 of 9.5 μM.
E4719	XYL-1	XYL-1 is a highly potent inhibitor of PARP7 with and IC50 of 0.6 nM. It could enhance the type-Ⅰinterferon signaling in vitro, and can be a potential candidate for developing cancer immunotherapy agents.
E5851^New	T26	T26( PARP1-IN-35) is a potent, selective, orally active, inhibitor of PARP1 capable of crossing the blood-brain barrier, with IC50 values of 0.2 nM. It exhibits significant antitumor efficacy and holds potential as a research treatment for breast cancer metastases.
E7366	Veliparib dihydrochloride	Veliparib dihydrochloride is an orally active and potent inhibitor of both PARP-1 and PARP-2 with Kis of 5.2 nM and 2.9 nM, respectively. It exhibit ability to cross the blood-brain barrier and potentiate DNA-damaging agents in preclinical tumor model.
E1518	DPQ	DPQ is a potent inhibitor of Poly (ADP-ribose) polymerase (PARP), with an IC50 of 40 nM for PARP1. It also suppresses macrophage-mediated inflammation and mitigates acute lung injury (ALI) induced by lipopolysaccharide (LPS) challenge in mice.
S8876	RK-287107	RK-287107 is a novel, potent and selective tankyrase inhibitor with antitumor activity. This compound inhibits tankyrase-1 and tankyrase-2 in vitro with IC50 of 14.3 nM and 10.6 nM.
S6745	JW55	JW55 is a potent and selective inhibitor of the canonical Wnt pathway that functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2).	Cell Discov, 2024, 10(1):39 Oncotarget, 2021, 12(7):674-685 Chin J Integr Med, 2021, 10.1007/s11655-021-3282-0
S6899	Licochalcone D	Licochalcone D (Lico D, LCD, LD), a flavonoid isolated from a Chinese medicinal plant Glycyrrhiza inflata, has antioxidant, anti-inflammatory and anti-cancer properties. This compound inhibits phosphorylation of NF-κB p65 in LPS signaling pathway. It inhibits JAK2, EGFR and Met (c-Met) activities and induces ROS-dependent apoptosis. This chemical also induces caspases activation and poly (ADP-ribose) polymerase (PARP) cleavage.
S0913	4',5,7-Trimethoxyflavone	4',5,7-Trimethoxyflavone (5,7,4'-Trimethoxyflavone, TMF) is a flavonoid isolated from Kaempferia parviflora (KP) that induces apoptosis. This compound increases sub-G1 phase, DNA fragmentation, annexin-V/PI staining and Bax/Bcl-xL ratio, activates caspase-3 and degrades poly (ADP-ribose) polymerase (PARP) protein.